@article{b5663dc07e704113bf33ed2066d02502,
title = "Journal-related Activities and Other Special Activities at the 2017 American Society of Anesthesiologists Meeting",
author = "Avram, {Michael J.} and Kharasch, {Evan D.} and Sachin Kheterpal and Rathmell, {James P.} and Sessler, {Daniel I.}",
note = "Funding Information: “Safety and Efficacy of Sufentanil Sublingual Tablet 30 μg by Age Group for the Treatment of Acute Pain in Medically Supervised Settings” by Karen DiDonato, M.S.N., Jacob L. Hutchins, M.D., James Miner, M.D., Harold Minkowitz, M.D., Pamela P. Palmer, M.D., Ph.D., AcelRx Pharmaceuticals, Redwood City, California; University of Minnesota, Minneapolis, Minnesota; Hennepin County Medical Center, Minneapolis, Minnesota; Memorial Hermann Memorial City Medical Center, Houston, Texas. The sufentanil sublingual tablet (SST) 30 μg is currently under review by the U.S. Food and Drug Administration and European Medicines Agency for treatment of moderate-to-severe acute pain in a medically supervised setting. After completion of the phase 3 program, which was sponsored by the U.S. Department of Defense, a safety and efficacy subgroup analysis by age group was performed across all four late-stage clinical trials. SST 30 μg has shown benefit across a range of patient ages as a noninvasive analgesic modality for short-term management of acute moderate-to-severe pain. Although the elderly should always be monitored closely in postoperative and trauma settings, results from these late-phase studies suggest that SST 30 μg is effective and well tolerated in this patient population.",
year = "2017",
month = oct,
day = "1",
doi = "10.1097/ALN.0000000000001832",
language = "English (US)",
volume = "127",
pages = "601--608",
journal = "Anesthesiology",
issn = "0003-3022",
publisher = "Lippincott Williams and Wilkins",
number = "4",
}